References
- MannucciPMTuddenhamEGThe hemophilias–from royal genes to gene therapyN Engl J Med2001344231773177911396445
- SrivastavaABrewerAKMauser-BunschotenEPGuidelines for the management of hemophiliaHaemophilia2013191e1e4722776238
- OladapoAOEpsteinJDWilliamsEItoDGringeriAValentinoLAHealth-related quality of life assessment in haemophilia patients on prophylaxis therapy: a systematic review of results from prospective clinical trialsHaemophilia2015215e344e35826390060
- GouwSCvan den BergHMFischerKIntensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN studyBlood2013121204046405523553768
- ShueyDJMccallusDEGiordanoTRNAi: gene-silencing in therapeutic interventionDrug Discov Today20027201040104612546893
- GaoKHuangLAchieving efficient RNAi therapy: progress and challengesActa Pharm Sin B201334213225
- HausseckerDCurrent issues of RNAi therapeutics delivery and developmentJ Control Release2014195495425111131
- ShettySVoraSKulkarniBContribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patientsBr J Haematol2007138454154417659055
- FranchiniMMontagnanaMTargherGInterpatient phenotypic inconsistency in severe congenital hemophilia: a systematic review of the role of inherited thrombophiliaSemin Thromb Hemost200935330731219452406
- BolligerDSzlamFSuzukiNMatsushitaTTanakaKAHeterozygous antithrombin deficiency improves in vivo haemostasis in factor VIII-deficient miceThromb Haemost201010361233123820352163
- PatnaikMMMollSInherited antithrombin deficiency: a reviewHaemophilia20081461229123919141163
- SehgalABarrosSIvanciuLAn RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophiliaNat Med201521549249725849132
- NairJKWilloughbyJLChanAMultivalent N-acetylgalactos-amine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencingJ Am Chem Soc201413649169581696125434769
- RagniMVTargeting antithrombin to treat hemophiliaN Engl J Med2015373438939126200986
- RagniMVGeorgievPMantTFitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia: updated results from a Phase 1 and Phase 1,2 extension study in patients without inhibitorsBlood20161282572
- PasiKJGeorgievPMantTFitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia: updated results from a phase 1 and phase 1,2 extension study in patients with inhibitorsBlood20161281397
- PasiKJRangarajanSGeorgievPTargeting of antithrombin in hemophilia A or B with RNAi therapyN Engl J Med2017377981982828691885
- PasiKJGeorgievPFitusiranMTAn investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia: interim results from a phase 2 extension study in patients with hemophilia A or B with and without inhibitorsRes Pract Thromb Haemost20171Suppl 125
- RochaPCarvalhoMLopesMAraújoFCosts and utilization of treatment in patients with hemophiliaBMC Health Serv Res20151548426502954
- AlnylamAlnylam Reports Patient Death in Fitusiran Clinical StudyNational Hemophilia Foundation2017 Available from: https://www.hemophilia.org/Newsroom/Industry-News/Alnylam-Reports-Patient-Death-in-Fitusiran-Clinical-StudyAccessed August 8, 2018
- QianKLiuJHuangSAkinAThrombin generation response with the addition of bypassing agents in plasma of patients treated with fitusiranHemophilia201824S5MP-219
- NegrierCRagniMVGeorgievPPerioperative management in patients with hemophilia receiving fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of hemophiliaBlood2017130Suppl 12366
- SridharanGLiuJQianKGoelVHuangSAkincAIn silico modeling of the impact of antithrombin lowering on thrombin generation in rare bleeding disordersBlood20171303659
- LiuJQianKHuangSColbergTEffect of antithrombin lowering on thrombin generation in rare bleeding disorder patient plasmaHemophilia201824S5TP-121